NEW
YORK, April 29, 2024 /PRNewswire/
-- Lucid Diagnostics Inc. (Nasdaq:
LUCD) ("Lucid" or the "Company") a commercial-stage, cancer
prevention medical diagnostics company, and majority-owned
subsidiary of PAVmed Inc. (Nasdaq: PAVM), is partnering with the
Esophageal Cancer Action Network (ECAN) to highlight Esophageal
Cancer Awareness Month. ECAN, a leading patient advocacy
organization focused on increasing esophageal cancer education,
advocacy, awareness, and research, was founded 15 years ago by
Mindy Mintz Mordecai following the
tragic death of her husband of esophageal cancer.
Lucid and ECAN are partnering to spread the potentially
life-saving message that heartburn (also known as acid reflux or
GERD) can lead to highly lethal esophageal cancer and that
esophageal cancer is preventable through early precancer detection.
Public service videos highlighting this message and encouraging
those at risk to get tested have been running on the iconic
seven-story Nasdaq billboard in New York
City's Times Square as part of Esophageal Cancer Awareness
Month.
"Esophageal cancer is one of the most lethal cancers and kills
over sixteen thousand Americans a year. Public awareness of the
link between esophageal cancer and heartburn, as well as the fact
that it can be prevented through early precancer detection, is
lacking," said Shaun O'Neil, Lucid's
President and Chief Operating Officer. "At Lucid Diagnostics, we
are proud of our long-standing collaboration with Mindy Mintz Mordecai and the ECAN team. ECAN has
been a critical voice supporting our efforts to expand patient
access to early precancer detection using EsoGuard."
"I started ECAN because of the glaring void in education related
to the link between reflux disease and esophageal cancer," said Ms.
Mordecai, President and Chief Executive Officer of ECAN. "This is
our 15th Esophageal Cancer Awareness Month, and we are
thrilled to see so many companies and individuals paying attention
and advocating for early, proactive screening. Lucid Diagnostics
has been a longtime supporter and collaborator with our
organization and we are fierce advocates of the Company's mission
to help prevent this devastating cancer before it starts."
About Lucid Diagnostics
Lucid Diagnostics Inc. is a
commercial-stage, cancer prevention medical diagnostics company,
and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on
the millions of patients with gastroesophageal reflux disease
(GERD), also known as chronic heartburn, who are at risk of
developing esophageal precancer and cancer. Lucid's
EsoGuard® Esophageal DNA Test, performed on samples
collected in a brief, noninvasive office procedure with its
EsoCheck® Esophageal Cell Collection Device - the first
and only commercially available tools designed with the goal of
preventing cancer and cancer deaths through widespread, early
detection of esophageal precancer in at-risk patients.
For more information, please visit www.luciddx.com and for more
information about its parent company PAVmed, please visit
www.pavmed.com.
About Esophageal Cancer Network (ECAN)
The Esophageal
Cancer Action Network (ECAN) is a non-profit, 501(c)(3)
organization supporting esophageal cancer patients and their
families. Their mission is to save lives by increasing awareness
about the link between acid reflux disease and cancer, promoting
early detection, supporting medical innovation to prevent, detect,
treat and cure esophageal cancer, and providing patients and
families with the latest, most reliable medical information and
compassionate support. ECAN's relentless advocacy has increased the
federal budget for esophageal cancer research by more than $15
million in the past three years and is expected drive millions more
in the years to come. Visit https://ecan.org/ for more
information.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-partners-with-the-esophageal-cancer-action-network-ecan-to-highlight-esophageal-cancer-awareness-month-302130055.html
SOURCE Lucid Diagnostics